Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ASKG129
- Development stage
- Preclinical
- Lead developer
- AskGene Pharma
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
01
Overview
ASKG129 is a recombinant fusion protein drug candidate developed by AskGene Pharma. It is designed as an anti-PD-1 antibody/interleukin-12 (IL-12) prodrug fusion molecule, combining the immune checkpoint blockade of PD-1 inhibition with the immunostimulatory effects of IL-12. The mechanism aims to enhance antitumor immune responses by simultaneously blocking PD-1-mediated immunosuppression and delivering IL-12 activity to stimulate T-cell function within the tumor microenvironment. The drug is being developed for cancer therapy, particularly solid tumors, using AskGene's SmartKine platform[1][2][3].
- Other names
- ASKG 129ASKG129ASKG-129
02
Targets
IL-12R (Interleukin-12 receptor)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on ASKG129.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ASKG129.